浙江新农化工股份有限公司 2023 年度审计报告 中国杭州市钱江新城新业路8号UDC时代大厦A座5-8层、12层、23层 Floors 5–8, 12 and 23, Block A, UDC Times Building, No 8 Xinye Road, Qianjiang New City, Hangzhou Tel. 0571-88879999 Fax. 0571-88879000 www.zhcpa.cn 行证明该审计报告是否由具有执业许可的会计师事务 十师行业统一监管平台（http://acc.mof.gov.cn） 您可使用手机"扫一扫"或进入 编码:浙2446F 目 录 | 页 次 | | | --- | --- | | 一、审计报告 | 1-6 | | 二、财务报表 | 7-18 | | (一) 合并资产负债表 | 7-8 | | (二) 合并利润表 | 9 | | (三) 合并现金流量表 | 10 | | (四) 合并所有者权益变动表 | 11-12 | | (五) 母公司资产负债表 | 13-14 | | (六) 母公司利润表 | 15 | | (七) 母公司现金流量表 | 16 | | ...

[Report Summary and Key Financial Indicators](index=6&type=section&id=Item%202.%20Company%20Profile%20and%20Key%20Financial%20Indicators) [Company Profile](index=6&type=section&id=Item%201.%20Company%20Information) Zhejiang Xinnong Chemical Co., Ltd. (stock code: 002942) is a Shenzhen-listed company specializing in the R&D, production, and sales of chemical pesticides and intermediates - The company is a chemical enterprise listed on the Shenzhen Stock Exchange, stock code **002942**, primarily engaged in the R&D, production, and sales of chemical pesticides[15](index=15&type=chunk) [Core Financial Data](index=7&type=section&id=Item%206.%20Key%20Accounting%20Data%20and%20Financial%20Indicators) In 2023, the company's performance significantly declined, with revenue decreasing by 34.22% to 821 million yuan and net profit attributable to shareholders turning from profit to loss at -25 million yuan Key Financial Indicators | Indicator | 2023 | 2022 | YoY Change | | :--- | :--- | :--- | :--- | | **Operating Revenue (yuan)** | 821,032,278.60 | 1,248,167,151.74 | -34.22% | | **Net Profit Attributable to Parent (yuan)** | -25,374,268.50 | 101,397,042.30 | -125.02% | | **Non-recurring Net Profit Attributable to Parent (yuan)** | -43,594,379.46 | 91,855,675.41 | -147.46% | | **Net Cash Flow from Operating Activities (yuan)** | 90,476,478.57 | 138,071,733.77 | -34.47% | | **Basic Earnings Per Share (yuan/share)** | -0.17 | 0.66 | -125.76% | | **Weighted Average Return on Net Assets** | -2.21% | 8.79% | -11.00 percentage points | | **Total Assets (yuan)** | 1,476,010,746.37 | 1,640,799,914.94 | -10.04% | | **Net Assets Attributable to Parent (yuan)** | 1,121,841,233.36 | 1,171,255,911.40 | -4.22% | [Quarterly Financial Performance](index=8&type=section&id=Item%208.%20Key%20Quarterly%20Financial%20Indicators) The company's 2023 performance showed a quarterly decline, turning to loss in Q3 and significantly widening in Q4, while operating cash flow improved in the latter half Quarterly Financial Indicators | Financial Indicator (yuan) | Q1 | Q2 | Q3 | Q4 | | :--- | :--- | :--- | :--- | :--- | | **Operating Revenue** | 275,296,537.41 | 209,537,984.85 | 176,637,399.08 | 159,560,357.26 | | **Net Profit Attributable to Parent** | 10,792,398.23 | 14,847,010.13 | -3,529,677.55 | -47,483,999.31 | | **Non-recurring Net Profit Attributable to Parent** | 3,253,361.65 | 13,396,428.82 | -7,298,608.89 | -52,945,561.04 | | **Net Cash Flow from Operating Activities** | -54,289,133.02 | 39,615,374.33 | 25,822,523.87 | 79,327,713.39 | [Dividend Distribution Plan](index=2&type=section&id=Important%20Notice%2C%20Table%20of%20Contents%2C%20and%20Definitions) The board proposed a 2023 profit distribution plan of a cash dividend of 2 yuan (tax inclusive) per 10 shares, based on total shares minus repurchased shares - The company's 2023 profit distribution plan proposes a cash dividend of **2 yuan (tax inclusive)** per **10 shares**, based on **153,209,930 shares** after deducting repurchased shares[4](index=4&type=chunk) [Management Discussion and Analysis](index=10&type=section&id=Item%203.%20Management%20Discussion%20and%20Analysis) [Industry Overview and Company Positioning](index=10&type=section&id=Item%201.%20Industry%20Conditions%20During%20the%20Reporting%20Period) In 2023, the domestic pesticide market faced intensified competition due to oversupply, driving a shift towards green pesticides and favoring integrated, R&D-capable companies, with the company's core product, Thiazinc, maintaining strong market competitiveness - In 2023, domestic pesticide market competition intensified, leading to oversupply and an expected increase in industry concentration[36](index=36&type=chunk) - Policies encourage the development of efficient, safe, and environmentally friendly pesticide varieties and formulations, with highly toxic and high-residue pesticides gradually exiting the market[36](index=36&type=chunk) - The company's core product, **Thiazinc**, is an independently developed fungicide with high market recognition and strong competitiveness in bacterial disease control[38](index=38&type=chunk) [Main Business and Products](index=11&type=section&id=Item%202.%20Main%20Businesses%20Engaged%20in%20During%20the%20Reporting%20Period) The company's main business covers the entire pesticide industry chain, from intermediates to formulations, with core products including Thiazinc fungicides and Chlorpyrifos/Triazophos insecticides; however, capacity utilization was generally low in 2023, and overseas sales accounted for 20.97% of total revenue Production Capacity and Utilization | Main Product | Designed Capacity | Capacity Utilization Rate | Capacity Under Construction | | :--- | :--- | :--- | :--- | | **Formulations** | 9,000 tons/year | 72.27% | 20,000 tons/year | | **Technical Concentrates** | 11,000 tons/year | 58.59% | 700 tons/year | | **Intermediates** | 28,800 tons/year | 31.51% | 6,500 tons/year | - The company's proprietary **Thiazinc** series formulations are estimated to hold an **11-13%** market share in bacterial disease control[54](index=54&type=chunk) - Overseas sales revenue in 2023 was **172 million yuan**, accounting for **20.97%** of total revenue, indicating a relatively small scale[59](index=59&type=chunk) [Core Competencies](index=18&type=section&id=Item%203.%20Analysis%20of%20Core%20Competencies) The company's core competencies include strong technological innovation, an integrated industrial chain, differentiated product advantages, a robust brand and market presence, and excellent safety and environmental management - The company possesses a comprehensive R&D system, recognized as a National High-Tech Enterprise and National Intellectual Property Advantage Enterprise, with **150 accumulated patents** (including **58 invention patents**) as of the reporting period end[60](index=60&type=chunk)[61](index=61&type=chunk) - The company adopts an integrated 'intermediate-technical concentrate-formulation' industrial chain model, effectively reducing transaction costs and ensuring product quality and stable supply[62](index=62&type=chunk) - The core product, **Thiazinc**, is a proprietary patented product with uniqueness and high recognition in bacterial disease control, having received multiple national and provincial science and technology awards[65](index=65&type=chunk) - The company has established a sales network covering over **20 provinces** nationwide and maintains long-term strategic partnerships with international agrochemical companies like BASF, Corteva, and Bayer[69](index=69&type=chunk) [Operating Results Analysis](index=20&type=section&id=Item%204.%20Analysis%20of%20Main%20Business) In 2023, the company's operating performance significantly declined due to industry downturn and price drops, but its formulation business showed resilience, increasing its revenue contribution despite overall revenue decrease [Overall Operating Review](index=20&type=section&id=1.%20Overview) The company actively responded to the agrochemical industry downturn by implementing differentiated strategies for formulations and industrial products, increasing R&D investment to 7.10% of revenue, and achieving zero safety and environmental incidents - Facing industry downturn, the company implemented a 'win by professionalism, system for future' strategy, prioritizing a differentiated approach led by the formulation business and a 'cost-performance' strategy for industrial products[74](index=74&type=chunk)[76](index=76&type=chunk) - R&D expenses in 2023 totaled **58.33 million yuan**, accounting for **7.10%** of operating revenue[78](index=78&type=chunk) [Revenue and Cost Analysis](index=21&type=section&id=2.%20Revenue%20and%20Costs) In 2023, total revenue decreased by 34.22% to 821 million yuan, with intermediates and technical concentrates experiencing significant declines in both revenue and gross margin due to market downturn and price drops Revenue and Gross Margin by Product | By Product | Operating Revenue (yuan) | YoY Revenue Change | Gross Margin | YoY Gross Margin Change | | :--- | :--- | :--- | :--- | :--- | | **Formulations** | 356,752,379.12 | -7.80% | 47.12% | -3.40 percentage points | | **Technical Concentrates** | 185,215,529.83 | -29.97% | -11.94% | -17.31 percentage points | | **Intermediates** | 256,564,409.37 | -54.28% | 9.11% | -7.83 percentage points | - Prices for technical concentrates and intermediate products showed a downward trend during the reporting period, primarily due to industry downturn and oversupply[85](index=85&type=chunk) [Expense Analysis](index=24&type=section&id=3.%20Expenses) Sales and administrative expenses remained stable in 2023, while financial expenses decreased due to reduced foreign exchange gains, and R&D expenses saw a 16.96% year-on-year decrease Key Expense Items | Expense Item | 2023 (yuan) | 2022 (yuan) | YoY Change | Main Change Explanation | | :--- | :--- | :--- | :--- | :--- | | **Selling Expenses** | 56,570,979.94 | 57,520,825.67 | -1.65% | No significant change | | **Administrative Expenses** | 96,546,522.89 | 91,129,118.33 | 5.94% | No significant change | | **Financial Expenses** | -4,037,649.98 | -12,766,428.95 | Not applicable | Primarily due to impact of USD exchange rate fluctuations on exchange gains | | **R&D Expenses** | 58,328,564.13 | 70,237,536.36 | -16.96% | No significant change | [R&D Investment](index=24&type=section&id=4.%20R%26D%20Investment) In 2023, total R&D investment was 60.28 million yuan, representing 7.34% of operating revenue, an increase from the previous year, with R&D efforts focused on process optimization, cost reduction, and new product development R&D Investment Overview | R&D Investment | 2023 | 2022 | Change Percentage | | :--- | :--- | :--- | :--- | | **R&D Investment Amount (yuan)** | 60,283,381.65 | 70,237,536.36 | -14.17% | | **R&D Investment as % of Revenue** | 7.34% | 5.63% | 1.71 percentage points | | **Number of R&D Personnel (persons)** | 174 | 178 | -2.25% | | **R&D Personnel as % of Total Staff** | 14.68% | 12.35% | 2.33 percentage points | [Cash Flow Analysis](index=25&type=section&id=5.%20Cash%20Flow) In 2023, net cash flow from operating activities decreased by 34.47% due to lower sales, while net cash outflow from financing activities significantly reduced due to decreased dividend distribution - Net cash flow from operating activities was **90,476,478.57 yuan**, a **34.47%** year-on-year decrease, primarily due to reduced cash received from sales of goods and services[96](index=96&type=chunk)[97](index=97&type=chunk) - Net cash outflow from financing activities decreased year-on-year, mainly due to a reduction in dividend distribution for the current year[97](index=97&type=chunk)[98](index=98&type=chunk) [Assets and Liabilities Status](index=26&type=section&id=Item%206.%20Analysis%20of%20Assets%20and%20Liabilities%20Status) As of 2023 year-end, total assets decreased by 10.04% to 1.476 billion yuan, while total liabilities decreased by 24.57% to 354 million yuan, improving the asset-liability ratio to 24.00% and reflecting a more stable financial structure - As of 2023 year-end, the company's total assets were **1.476 billion yuan**, a **10.04%** year-on-year decrease; total liabilities were **354 million yuan**, a **24.57%** year-on-year decrease[99](index=99&type=chunk)[314](index=314&type=chunk) - The asset-liability ratio at year-end was **24.00%**, a decrease from **28.62%** at the beginning of the period, indicating an improved financial structure[759](index=759&type=chunk) - The book value of restricted assets at year-end was **16.90 million yuan**, primarily consisting of bank acceptance bill and forward foreign exchange settlement and sales deposits, a significant decrease from **52.74 million yuan** at the beginning of the period[102](index=102&type=chunk)[103](index=103&type=chunk) [Future Outlook and Risks](index=38&type=section&id=Item%2011.%20Outlook%20on%20the%20Company%27s%20Future%20Development) The company anticipates accelerated green transformation and consolidation in the pesticide industry, focusing on a differentiated strategy led by formulations and Thiazinc, while addressing market competition, raw material price volatility, and safety/environmental risks [Development Strategy and 2024 Operating Plan](index=39&type=section&id=2.%20Company%20Development%20Strategy) The company's development strategy focuses on differentiation, with formulations as the lead, combining innovation and imitation, and synergistic development of chemical and biological pesticides, supported by a 2024 plan to optimize marketing, enhance R&D, strengthen QEHS, and build professional teams - Company strategy: Focus on differentiation, with formulations as the lead, combining innovation and imitation, and an integrated model of synergistic development of chemical and biological pesticides[142](index=142&type=chunk) - 2024 plan: Continue to focus on **6+1 core crops**, improve channel management, expand strategic products, and accelerate new product development in chemical pesticides and biological formulations[143](index=143&type=chunk)[144](index=144&type=chunk) [Key Risks and Countermeasures](index=40&type=section&id=4.%20Potential%20Risk%20Factors%20and%20Countermeasures) The company faces key risks including market competition, raw material price volatility, safety and environmental pressures, and operational management challenges from expansion, which it addresses through continuous technical upgrades, procurement control, increased safety/environmental investment, and improved management structures - Key risks include market competition, raw material price fluctuations, production safety, environmental protection, and operational management risks[147](index=147&type=chunk)[148](index=148&type=chunk)[149](index=149&type=chunk)[150](index=150&type=chunk)[151](index=151&type=chunk) [Corporate Governance and Internal Control](index=42&type=section&id=Item%204.%20Corporate%20Governance) [Corporate Governance Structure](index=42&type=section&id=Item%201.%20Basic%20Status%20of%20Corporate%20Governance) The company operates in strict compliance with laws and regulations, maintaining a sound corporate governance structure with independent assets, personnel, finance, organization, and operations, ensuring effective checks and balances - The company's corporate governance structure is sound, compliant with laws and regulations, and maintains independence from the controlling shareholder in terms of assets, personnel, finance, organization, and operations[155](index=155&type=chunk)[157](index=157&type=chunk) [Directors, Supervisors, and Senior Management](index=44&type=section&id=Item%205.%20Information%20on%20Directors%2C%20Supervisors%2C%20and%20Senior%20Management) During the reporting period, the company experienced a change in senior management with the resignation of the former Vice General Manager and CFO, Mr. He Hongyun, and the appointment of Ms. Ding Zhenzhen as the new CFO - During the reporting period, Vice General Manager and CFO He Hongyun resigned, and the company appointed **Ding Zhenzhen** as the new CFO[164](index=164&type=chunk) [Internal Control](index=54&type=section&id=Item%2012.%20Construction%20and%20Implementation%20of%20Internal%20Control%20System%20During%20the%20Reporting%20Period) The company continuously improved its internal control system, and as of December 31, 2023, maintained effective internal controls over financial reporting in all material aspects, with no significant deficiencies identified by the board or auditors - The company's board of directors believes that the internal control design is sound and effectively implemented, with no significant deficiencies[197](index=197&type=chunk) - The accounting firm issued a standard unqualified audit opinion on the effectiveness of the company's internal controls over financial reporting as of December 31, 2023[202](index=202&type=chunk) [Environmental, Social Responsibility, and Other Significant Matters](index=56&type=section&id=Item%205.%20Environmental%20and%20Social%20Responsibility) [Environmental Protection](index=56&type=section&id=Item%201.%20Major%20Environmental%20Issues) The company and its subsidiaries are key pollutant discharge units, adhering to environmental regulations; however, subsidiary Jiangsu Xinnong received a 190,000 yuan fine for wastewater discharge exceedance, which has since been rectified - The company and its subsidiaries, Xinnong Co., Xinnong Technology, and Jiangsu Xinnong, are all designated as key pollutant discharge units by environmental protection authorities[205](index=205&type=chunk) - During the reporting period, subsidiary Jiangsu Xinnong was fined **190,000 yuan** for exceeding wastewater total nitrogen discharge limits and has completed rectification[224](index=224&type=chunk) [Social Responsibility](index=61&type=section&id=Item%202.%20Social%20Responsibility%20Status) The company actively fulfills its social responsibilities, including legal compliance, protecting stakeholder rights, ensuring employee welfare, maintaining supplier/customer relations, and engaging in public welfare, consistently providing cash dividends since listing and achieving zero safety accidents in 2023 - The company prioritizes investor returns, having distributed cash dividends annually since its listing, with cumulative distributed profits totaling **289.2 million yuan**[227](index=227&type=chunk) - All major production bases have established comprehensive safety management systems, with **no safety production accidents** occurring throughout 2023[233](index=233&type=chunk)[235](index=235&type=chunk)[238](index=238&type=chunk) [Other Significant Matters](index=64&type=section&id=Item%206.%20Significant%20Matters) During the reporting period, the company fulfilled commitments, had no major litigation or related-party transactions, changed accounting policies due to new regulations, extended the '1,000 tons/year Pyraclostrobin' project, and both the company and Taizhou Xinnong were re-certified as high-tech enterprises - The company's fundraising project, 'Annual Production of **1,000 tons of Pyraclostrobin** and By-product **430 tons of Sodium Chloride Project**,' had its expected usable date extended due to process optimization and debugging[274](index=274&type=chunk) - Both the company and its wholly-owned subsidiary, Taizhou Xinnong Technology Co., Ltd., were re-certified as High-Tech Enterprises, valid for three years, entitling them to a preferential corporate income tax rate of **15%**[274](index=274&type=chunk)[275](index=275&type=chunk) [Share Changes and Shareholder Information](index=74&type=section&id=Item%207.%20Share%20Changes%20and%20Shareholder%20Information) [Share Changes](index=74&type=section&id=Item%201.%20Share%20Change%20Status) During the reporting period, the company's total share capital remained at 156 million shares, with a structural change in restricted and unrestricted shares due to the former supervisor's departure and subsequent release of his shares from restrictions - Total share capital remained unchanged at **156,000,000 shares** during the reporting period, with a structural change between restricted and unrestricted shares due to a senior executive's departure[278](index=278&type=chunk) [Major Shareholder Information](index=75&type=section&id=Item%203.%20Shareholder%20and%20Actual%20Controller%20Information) As of the reporting period end, the company had 9,383 shareholders, with Zhejiang Xinhui Investment Co., Ltd. as the controlling shareholder (54.50%), and the Xu Qunhui, Xu Yuexing, Pan Yuyan family as the actual controllers, collectively holding 64.31% of shares Top Shareholders | Shareholder Name | Shareholder Nature | Shareholding Percentage | Number of Shares Held at Period End | | :--- | :--- | :--- | :--- | | **Zhejiang Xinhui Investment Co., Ltd.** | Domestic Non-State-owned Legal Person | 54.50% | 85,020,000 | | **Xu Qunhui** | Domestic Natural Person | 5.06% | 7,897,500 | | **Pan Yuyan** | Domestic Natural Person | 3.50% | 5,460,000 | | **Hu Hong** | Domestic Natural Person | 2.31% | 3,599,700 | | **Guotai Juxin Value Advantage Mixed** | Fund | 1.95% | 3,045,900 | - The company's actual controllers are **Xu Qunhui**, **Xu Yuexing**, and **Pan Yuyan**, with Xu Yuexing and Pan Yuyan being a married couple and Xu Qunhui's parents[284](index=284&type=chunk)[288](index=288&type=chunk) [Financial Report and Audit Opinion](index=81&type=section&id=Item%2010.%20Financial%20Report) [Audit Report](index=81&type=section&id=Item%201.%20Audit%20Report) Zhonghui Certified Public Accountants (Special General Partnership) issued a standard unqualified audit opinion on the company's 2023 financial statements, confirming fair presentation in all material aspects, with revenue recognition identified as a key audit matter - The auditing firm issued a standard unqualified audit opinion[296](index=296&type=chunk) - A key audit matter was 'revenue recognition from main operations' due to its material amount and inherent risk of management override[297](index=297&type=chunk)[298](index=298&type=chunk) [Significant Accounting Policy Changes](index=69&type=section&id=Item%206.%20Explanation%20of%20Changes%20in%20Accounting%20Policies%2C%20Accounting%20Estimates%2C%20or%20Significant%20Accounting%20Error%20Corrections%20Compared%20to%20Prior%20Year%27s%20Financial%20Report) During the reporting period, the company changed its accounting policies in accordance with 'Interpretation No. 16 of Accounting Standards for Business Enterprises' issued by the Ministry of Finance, primarily concerning deferred income tax related to single transactions, with retrospective adjustments made to relevant financial statement items - The company adopted 'Interpretation No. 16 of Accounting Standards for Business Enterprises' issued by the Ministry of Finance starting January 1, 2023, and retrospectively adjusted deferred income tax arising from related transactions[253](index=253&type=chunk)[507](index=507&type=chunk) [Notes to Major Items in Consolidated Financial Statements](index=130&type=section&id=Item%207.%20Notes%20to%20Consolidated%20Financial%20Statement%20Items) Financial statement notes indicate decreases in accounts receivable and inventory, with bad debt provision reversals and inventory/fixed asset impairment provisions reflecting asset quality management pressures, while non-recurring gains partially offset operating losses - Accounts receivable balance at period-end was **91.19 million yuan**, a significant decrease from **147 million yuan** at the beginning of the period; **2.65 million yuan** in bad debt provisions were reversed this period[521](index=521&type=chunk)[527](index=527&type=chunk) - Inventory book value at period-end was **102 million yuan**, a decrease from **155 million yuan** at the beginning of the period; **11.57 million yuan** in inventory impairment provisions were recognized this period, mainly for finished goods[557](index=557&type=chunk)[559](index=559&type=chunk) - Fixed asset impairment provisions of **6.74 million yuan** were recognized this period, primarily for machinery and equipment no longer expected to be in use[569](index=569&type=chunk)[573](index=573&type=chunk) - Total non-recurring gains and losses for the current period amounted to **18.22 million yuan**, primarily comprising **9.36 million yuan** in government grants and **12.40 million yuan** in financial asset investment-related gains/losses[818](index=818&type=chunk)

2023 年度非经营性资金占用及其他关联资金往来情况汇总表 单位：万元 非经营性资金占用 资金占用方名称 占用方与上市 公司的关联关 系 上市公司核算 的会计科目 2023 年年期 初占用资金 余额 2023 年年度占用 累计发生金额 （不含利息） 2023 年年度占 用资金的利息 （如有） 2023 年年度偿 还累计发生金 额 2023 年年期末 占用资金余额 占用形成原因 占用性质 控股股东、实际控制 人及其附属企业 非经营性占用 小计 - - - - 前控股股东、实际控 制人及其附属企业 非经营性占用 小计 - - - - 其他关联方及其附 属企业 非经营性占用 小计 - - - - 总计 - - - - | | | 往来方与上市 | 上市公司核算 | 2023 年年期 | 2023 年年度往来 | | 2023 年年度往 | 2023 | 年年度偿 | 2023 年年期末 | | 往来性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 其他关联资金往来 | 资金往来方名称 | 公司 ...

根据中国证券监督管理委员会《上市公司独立董事管理办法》、《深圳证券交 易所股票上市规则》、《深圳证券交易所上市公司自律监管指引第 1 号——主板上 市公司规范运作》等要求，浙江新农化工股份有限公司（以下简称"公司"）董 事会，就公司在任独立董事刘亚萍、董黎明、徐关寿的独立性情况进行评估并出 具如下专项意见： 经核查独立董事刘亚萍、董黎明、徐关寿的任职经历以及签署的相关自查文 件，上述人员未在公司担任除独立董事、董事会专门委员会委员以外的任何职务， 也未在公司主要股东公司担任任何职务，与公司以及主要股东之间不存在利害关 系或其他可能妨碍其进行独立客观判断的关系。因此，公司独立董事符合《上市 公司独立董事管理办法》、《深圳证券交易所上市公司自律监管指引第 1 号——主 板上市公司规范运作》中对独立董事独立性的相关要求。 浙江新农化工股份有限公司 董事会 2024 年 4 月 24 日 浙江新农化工股份有限公司 关于独立董事独立性情况的专项意见 ...

浙江新农化工股份有限公司 《公司章程》修订对照表 | 序 号 | 修订前 | 修订后 | | --- | --- | --- | | 6 | 第八十八条 股东大会对提案进行表决 监票。审议事项与股东有利害关系的， | 第八十八条 股东大会对提案进行表决前， 审议事项与股东有关联关系的，相关股东 | | | 前，应当推举 2 名股东代表参加计票和 | | | | | 应当推举 2 名股东代表参加计票和监票。 | | | 相关股东及代理人不得参加计票、监 | | | | 票。 | 及代理人不得参加计票、监票。 | | 7 | | 各章节序号顺延 | （经公司第六届董事会第九次会议审议通过，尚需提交 2023 年年度股东大会审议） | 序 | 修订前 | 修订后 | | --- | --- | --- | | 号 | | | | | | 东大会的，须书面通知董事会，同时向公 | | | 第五十一条 监事会或股东决定自行召 集股东大会的，须书面通知董事会，同 | 第五十一条 监事会或股东决定自行召集股 | | | 时向公司所在地中国证监会派出机构和 | 司所在地中国证监会派出机构和证券交易 | | | 证券交易所备案 ...

证券代码：002942 证券简称：新农股份 公告编号：2024-019 浙江新农化工股份有限公司 关于 2024 年度拟申请银行综合授信的公告 浙江新农化工股份有限公司（以下简称"公司"）于 2024 年 4 月 23 日召开 第六届董事会第九次会议审议通过《关于 2024 年度拟申请银行综合授信的议案》， 该事项尚需提交公司 2023 年度股东大会审议。现就向银行申请综合授信额度事 项公告如下： 一、申请授信额度情况 为满足日常生产经营的资金需求，积极拓宽资金渠道，增强公司可持续发展 能力，2024 年公司拟向商业银行申请不超过人民币 10.50 亿元的综合授信额度。 以上授信额度不等于公司及子公司的融资金额，具体融资金额将视公司及子公司 生产经营的实际资金需求确定。部分拟申请的综合授信额度明细如下： 单位：万元（人民币） | 授信银行 | 授信额度 | | | --- | --- | --- | | 中国建设银行股份有限公司 | | 40,000 | | 中国银行股份有限公司 | | 15,000 | | 中国工商银行股份有限公司 | | 20,000 | | 浙商银行股份有限公司 | | 10,000 ...

浙江新农化工股份有限公司 章 程 2024 年 4 月 | | | | 第一章 | 总则 1 | | --- | --- | | 第二章 | 经营宗旨和范围 2 | | 第三章 | 股份 2 | | 第一节 | 股份发行 2 | | 第二节 | 股份增减和回购 3 | | 第三节 | 股份转让 4 | | 第四章 | 股东和股东大会 5 | | 第一节 | 股东 5 | | 第二节 | 股东大会的一般规定 8 | | 第三节 | 股东大会的召集 10 | | 第四节 | 股东大会的提案与通知 11 | | 第五节 | 股东大会的召开 13 | | 第六节 | 股东大会的表决和决议 15 | | 第五章 | 董事会 19 | | 第一节 | 董事 19 | | 第二节 | 董事会 22 | | 第六章 | 总经理及其他高级管理人员 26 | | 第七章 | 监事会 28 | | 第一节 | 监事 28 | | 第二节 | 监事会 28 | | 第八章 | 财务会计制度、利润分配和审计 30 | | 第一节 | 财务会计制度 30 | | 第二节 | 内部审计 33 | | 第三节 | 会计师事务所的聘任 33 ...

浙江新农化工股份有限公司 2024 年 4 月 董事会薪酬与考核委员会工作细则 | 第一章 | 总则 1 | | --- | --- | | 第二章 | 人员组成 1 | | 第三章 | 薪酬与考核委员会的职责权限 2 | | 第四章 | 薪酬与考核委员会的决策程序 3 | | 第五章 | 薪酬与考核委员会的议事规则 3 | | 第六章 | 附则 4 | 浙江新农化工股份有限公司 董事会薪酬与考核委员会工作细则 浙江新农化工股份有限公司 董事会薪酬与考核委员会工作细则 第一章 总则 第一条 为规范浙江新农化工股份有限公司（以下简称"公司"）董事、管 理人员的薪酬及考核，完善公司治理结构，根据《中华人民共和国公司法》、《上 市公司治理准则》、《浙江新农化工股份有限公司章程》（以下简称"《公司章 程》"）及其他有关规定，公司特设立董事会薪酬与考核委员会，并制定本工作 细则。 第二条 董事会薪酬与考核委员会是董事会设立的专门工作机构，主要负责 制定公司董事及高级管理人员的考核标准并进行考核；负责制定、审查公司董事 及高级管理人员的薪酬政策与方案，对董事会负责。 第二章 人员组成 第三条 薪酬与考核委员会成员由三名董 ...

证券代码：002942 证券简称：新农股份 公告编号：2024-018 浙江新农化工股份有限公司 关于续聘 2024 年度审计机构的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江新农化工股份有限公司（以下简称"公司"）于 2024 年 4 月 23 日召开 第六届董事会第九次会议，会议以 9 票同意，0 票弃权，0 票反对的表决结果审 议通过了《关于续聘 2024 年度审计机构的议案》，具体情况如下： 一、续聘会计师事务所事项的情况说明 （一）机构信息 1.基本信息 中汇会计师事务所，于 2013 年 12 月转制为特殊普通合伙，管理总部设立于 杭州，系原具有证券、期货业务审计资格的会计师事务所之一，长期从事证券服 务业务。 事务所名称：中汇会计师事务所（特殊普通合伙） 成立日期：2013 年 12 月 19 日 组织形式：特殊普通合伙 注册地址：杭州市上城区新业路 8 号华联时代大厦 A 幢 601 室 中汇会计师事务所（特殊普通合伙）（以下简称"中汇"）具有从事证券业务 资格，具备为上市公司提供审计服务的经验与能力。在担任公司审计机构期间， 遵 ...

光大证券股份有限公司 关于浙江新农化工股份有限公司 2023 年度募集资金存放与使用情况的专项核查报告 根据《证券发行上市保荐业务管理办法》《深圳证券交易所上市公司自律监 管指引第 13 号——保荐业务》等法律法规的相关规定，光大证券股份有限公司 （以下简称"光大证券"或"保荐机构"）作为浙江新农化工股份有限公司（以下简 称"新农股份"或"公司"）的保荐机构，持续督导期至 2020 年 12 月 31 日止。截 至 2023 年 12 月 31 日，公司首次公开发行股票募集资金尚未使用完毕，根据相 关规定，光大证券对公司的募集资金使用履行持续督导职责。光大证券在认真审 阅董事会《浙江新农化工股份有限公司 2023 年度募集资金存放与实际使用情况 的专项报告》及中汇会计师事务所（特殊普通合伙）出具的《年度募集资金存放 与使用情况鉴证报告》的基础上，现就其 2023 年度募集资金存放与使用情况核 查如下： 一、 募集资金的存放、使用及专户余额情况 （一） 首次公开发行实际募集资金金额、资金到位时间 根据公司 2017 年 3 月 23 日召开的 2017 年第一次临时股东大会审议，并经 中国证券监督管理委员会《关 ...